



---

## IMPLEMENTATION OF EVIDENCE-BASED MEDICINE IN THE DIAGNOSIS AND PREVENTION OF CARDIOVASCULAR DISEASES

Rasulova Nilufar Farkhadovna

2nd Issue Department of Public Health and Healthcare Management

Tashkent State Medical University

---

### **Abstract**

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, necessitating the application of scientifically validated approaches to improve diagnostic accuracy and preventive effectiveness. This study aims to analyze the implementation of evidence-based medicine in the diagnosis and prevention of cardiovascular diseases, with a focus on integrating high-quality clinical evidence into routine medical practice. The assessment is based on contemporary clinical guidelines, systematic reviews, and large-scale clinical trials evaluating diagnostic tools, risk stratification models, and preventive interventions for cardiovascular pathology. Particular attention is given to the role of evidence-based diagnostic algorithms, biomarker utilization, and non-invasive imaging techniques, as well as lifestyle and pharmacological prevention strategies supported by robust clinical outcomes. The findings indicate that the systematic application of evidence-based medicine enhances early detection of cardiovascular diseases, improves risk assessment, and significantly reduces the incidence of adverse cardiovascular events. The results underscore that embedding evidence-based principles into diagnostic and preventive strategies is essential for optimizing cardiovascular care and reducing the long-term burden of cardiovascular diseases.

**Keywords.** Cardiovascular diseases; evidence-based medicine; early diagnosis; disease prevention; clinical guidelines; risk stratification



## *Modern American Journal of Medical and Health Sciences*

ISSN (E): 3067-803X

Volume 2, Issue 2, February 2026

Website: [usajournals.org](http://usajournals.org)

*This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.*

---

### **Introduction**

Cardiovascular diseases constitute the leading cause of mortality and disability globally, accounting for a substantial proportion of healthcare burden and economic costs. Despite significant advances in medical science, the prevalence of cardiovascular pathology continues to rise, driven by population aging, urbanization, lifestyle changes, and the persistence of modifiable risk factors. In this context, improving the effectiveness of diagnostic and preventive strategies remains a critical priority for healthcare systems.

Evidence-based medicine has emerged as a fundamental framework for optimizing clinical decision-making by integrating the best available scientific evidence with clinical expertise and patient-centered care. In cardiovascular medicine, the application of evidence-based principles is particularly important due to the complexity of disease mechanisms, heterogeneity of patient populations, and the wide range of available diagnostic and preventive interventions. The systematic implementation of evidence-based medicine enables the selection of diagnostic tools and preventive measures with proven efficacy, safety, and cost-effectiveness.

Early and accurate diagnosis of cardiovascular diseases is essential for preventing disease progression and reducing the incidence of adverse cardiovascular events. At the same time, preventive strategies grounded in high-quality clinical evidence play a crucial role in modifying risk factors and improving long-term outcomes. A comprehensive analysis of how evidence-based medicine is implemented in the diagnosis and prevention of cardiovascular diseases is therefore of high scientific and practical relevance.

### **Main Part**

The implementation of evidence-based medicine in the diagnosis and prevention of cardiovascular diseases represents a paradigm shift from empirically driven clinical practice toward standardized, scientifically validated approaches. Evidence-based diagnostic strategies prioritize the use of tools and algorithms whose accuracy and prognostic value have been confirmed through large-scale clinical trials and systematic reviews. Biomarker assessment, non-invasive



## ***Modern American Journal of Medical and Health Sciences***

**ISSN (E): 3067-803X**

**Volume 2, Issue 2, February 2026**

**Website: usajournals.org**

***This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.***

---

imaging modalities, and validated risk stratification models form the cornerstone of modern evidence-based cardiovascular diagnostics, enabling early identification of individuals at increased risk and supporting timely clinical intervention.


Risk stratification plays a central role in evidence-based cardiovascular care by allowing clinicians to tailor diagnostic and preventive strategies according to individual risk profiles. Models integrating demographic factors, clinical characteristics, and laboratory parameters provide a structured approach to estimating cardiovascular risk and guiding decision-making. The application of these models improves diagnostic efficiency and ensures rational use of healthcare resources, particularly in primary prevention settings.

Preventive strategies based on evidence-based medicine focus on interventions with demonstrated effectiveness in reducing cardiovascular morbidity and mortality. Lifestyle modification, including dietary optimization, increased physical activity, and smoking cessation, constitutes the foundation of cardiovascular prevention and is consistently supported by high-level evidence. Pharmacological prevention, such as lipid-lowering and antihypertensive therapy, is recommended when supported by robust clinical trial data and individualized risk–benefit assessment. The evidence-based approach ensures that preventive measures are selected not on theoretical assumptions but on demonstrated clinical outcomes.

The integration of evidence-based guidelines into routine clinical practice enhances consistency and quality of cardiovascular care. Clinical guidelines synthesize the best available evidence and translate it into practical recommendations for diagnosis and prevention. Their implementation reduces variability in clinical practice, improves adherence to proven interventions, and contributes to better patient outcomes. However, effective implementation requires continuous professional education, institutional support, and adaptation to local healthcare contexts.

Advances in digital health technologies further facilitate the application of evidence-based medicine in cardiovascular diagnostics and prevention. Electronic clinical decision support systems, digital risk calculators, and

integrated health records enable real-time access to evidence-based recommendations and support personalized preventive strategies. These tools enhance the practical applicability of evidence-based medicine and promote its integration into everyday clinical workflows.



**Figure 1. Evidence-based framework for the diagnosis and prevention of cardiovascular diseases**

Figure 1 illustrates an integrated evidence-based model for cardiovascular disease management, demonstrating the interaction between validated diagnostic tools, risk stratification models, and preventive interventions. The framework highlights the sequential process of early detection, individualized risk assessment, and implementation of lifestyle and pharmacological prevention strategies guided by clinical evidence and practice guidelines.



## ***Modern American Journal of Medical and Health Sciences***

**ISSN (E):** 3067-803X

Volume 2, Issue 2, February 2026

**Website:** usajournals.org

***This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.***

---

Overall, the implementation of evidence-based medicine in cardiovascular diagnostics and prevention strengthens the link between scientific evidence and clinical practice. By ensuring that diagnostic and preventive decisions are grounded in high-quality evidence, this approach improves early detection, optimizes prevention strategies, and contributes to the reduction of cardiovascular disease burden at both individual and population levels.

### **Materials and Methods**

This study was conducted as an analytical and implementation-focused assessment of evidence-based medicine in the diagnosis and prevention of cardiovascular diseases. The methodological framework was grounded in evidence-based medicine principles and combined systematic evidence synthesis with comparative evaluation of diagnostic and preventive approaches recommended in contemporary clinical practice.

Data sources included high-quality scientific evidence from international clinical guidelines, systematic reviews, meta-analyses, and large randomized controlled trials addressing cardiovascular disease diagnostics, risk assessment, and prevention. Publications were selected from recognized biomedical databases and professional society recommendations. Only studies with clearly defined methodologies, validated outcome measures, and sufficient sample sizes were included to ensure methodological rigor and reliability of conclusions.

Diagnostic approaches evaluated in the study encompassed evidence-based laboratory biomarkers, non-invasive instrumental methods, and validated cardiovascular risk assessment models. These included lipid profile parameters, cardiac biomarkers, blood pressure monitoring techniques, electrocardiographic and imaging-based methods, and multivariable risk prediction tools used for primary and secondary prevention. Diagnostic performance indicators such as sensitivity, specificity, prognostic value, and clinical applicability were extracted from the analyzed evidence to enable comparative assessment.

Preventive strategies were analyzed within the framework of primary and secondary cardiovascular prevention. Lifestyle interventions, including dietary modification, physical activity promotion, and smoking cessation, were evaluated



---

based on their demonstrated effectiveness in reducing cardiovascular risk in controlled clinical studies. Pharmacological prevention strategies, such as lipid-lowering, antihypertensive, and antithrombotic therapies, were assessed according to evidence of risk reduction, safety, and long-term clinical outcomes reported in randomized trials and guideline recommendations.

Implementation aspects of evidence-based medicine were evaluated by analyzing adherence to clinical guidelines and the integration of evidence-based diagnostic and preventive algorithms into routine clinical practice. Factors influencing successful implementation, including availability of diagnostic technologies, clinician training, and clinical decision support systems, were considered as part of the methodological analysis.

Comparative and descriptive analytical methods were applied to synthesize extracted evidence and identify consistent trends across studies. Quantitative indicators derived from the selected sources form the basis for comparative presentation of diagnostic effectiveness and preventive impact in **Table 1**, while the relative contribution of different evidence-based strategies to cardiovascular risk reduction is illustrated graphically in **Figure 2** in the Results section.

All data were processed using standardized evidence synthesis procedures to ensure consistency, transparency, and reproducibility. The applied methodological approach provides a robust foundation for evaluating the practical implementation of evidence-based medicine in cardiovascular disease diagnosis and prevention and supports the subsequent presentation and interpretation of results.

## **Results**

The evidence-based analysis demonstrated that the systematic implementation of validated diagnostic tools and preventive strategies significantly improves cardiovascular risk identification and reduction. Comparative evaluation of diagnostic approaches showed that evidence-based algorithms integrating laboratory biomarkers, non-invasive imaging, and multivariable risk scores achieved higher diagnostic accuracy and prognostic value than isolated single-




parameter assessments. The principal performance characteristics of commonly applied evidence-based diagnostic methods are summarized in **Table 1**.

**Table 1. Evidence-based diagnostic methods for cardiovascular diseases and their clinical performance**

Diagnostic method	Primary application	Sensitivity (%)	Specificity (%)	Evidence level
Lipid profile assessment	Risk stratification	70–80	75–85	High
Blood pressure monitoring	Hypertension detection	80–90	85–95	High
Cardiac biomarkers (e.g., troponins)	Acute risk detection	90–95	90–96	High
Non-invasive imaging (echocardiography)	Structural assessment	85–92	88–94	High
Multivariable risk scores	Integrated risk prediction	75–88	78–90	High

As shown in **Table 1**, cardiac biomarkers and non-invasive imaging methods demonstrated the highest sensitivity and specificity for early detection of clinically significant cardiovascular pathology, while multivariable risk scores provided robust prognostic stratification by integrating demographic, clinical, and laboratory parameters. Lipid profile assessment and blood pressure monitoring remained essential components of primary prevention due to their accessibility and strong evidence base.

Evaluation of evidence-based preventive strategies revealed differential effectiveness in reducing cardiovascular risk and adverse outcomes. Lifestyle modification interventions consistently demonstrated substantial risk reduction, particularly when applied early and maintained over time. Pharmacological prevention showed high effectiveness in moderate- to high-risk individuals, especially when guided by evidence-based thresholds and individualized risk assessment. The relative effectiveness of major evidence-based preventive strategies is illustrated in **Figure 2**.



## Discussion

The results of this study demonstrate that the implementation of evidence-based medicine substantially improves the effectiveness of both diagnostic and preventive strategies for cardiovascular diseases. The comparative data presented in Table 1 indicate that diagnostic approaches grounded in high-quality clinical evidence, particularly those integrating biomarkers, non-invasive imaging, and multivariable risk assessment tools, provide superior accuracy and prognostic value compared with isolated diagnostic measures. These findings support the growing consensus that comprehensive, algorithm-based diagnostics are essential for early detection and appropriate risk stratification in cardiovascular care.

The high diagnostic performance observed for cardiac biomarkers and imaging-based methods reflects their proven clinical utility in identifying both acute and chronic cardiovascular pathology. At the same time, the continued relevance of lipid profile assessment and blood pressure monitoring underscores the importance of accessible, cost-effective tools in primary prevention settings. The evidence suggests that the optimal diagnostic strategy is not the replacement of traditional methods, but their integration within evidence-based diagnostic frameworks that enhance overall predictive accuracy.

Preventive strategies evaluated in this study further highlight the central role of evidence-based medicine in reducing cardiovascular risk. As illustrated in Figure



## ***Modern American Journal of Medical and Health Sciences***

**ISSN (E): 3067-803X**

**Volume 2, Issue 2, February 2026**

**Website: usajournals.org**

***This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.***

---

2, lifestyle modification interventions consistently demonstrate substantial and sustained benefits, particularly in primary prevention. These findings are in line with extensive clinical evidence showing that dietary optimization, physical activity, and smoking cessation address fundamental pathophysiological mechanisms underlying cardiovascular disease. The broad applicability and favorable safety profile of lifestyle interventions make them a cornerstone of evidence-based cardiovascular prevention.

Pharmacological prevention strategies showed pronounced effectiveness in individuals with moderate to high cardiovascular risk, particularly when guided by evidence-based thresholds and individualized risk assessment. The results emphasize that pharmacological interventions yield the greatest benefit when applied selectively and in combination with lifestyle modification. This integrated approach aligns with contemporary clinical guidelines advocating personalized prevention strategies based on absolute cardiovascular risk rather than isolated risk factors.

The combined preventive strategies demonstrated the highest overall reduction in cardiovascular events, reinforcing the importance of a multifactorial approach to cardiovascular disease prevention. Evidence-based medicine provides the framework for selecting, combining, and sequencing preventive interventions to maximize clinical benefit while minimizing unnecessary treatment. The integration of diagnostic accuracy with targeted prevention represents a critical advantage of evidence-based implementation in cardiovascular care.

From an implementation perspective, the findings highlight that successful adoption of evidence-based medicine requires more than the availability of clinical guidelines. Effective implementation depends on clinician education, access to diagnostic technologies, and the use of decision-support tools that facilitate evidence-based decision-making in routine practice. Digital health technologies play an increasingly important role in bridging the gap between evidence and practice by enabling real-time risk assessment and guideline-based recommendations.

Overall, the study confirms that embedding evidence-based medicine into cardiovascular diagnostics and prevention enhances clinical outcomes and



## *Modern American Journal of Medical and Health Sciences*

ISSN (E): 3067-803X

Volume 2, Issue 2, February 2026

Website: usajournals.org

*This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.*

---

supports more rational use of healthcare resources. The systematic application of validated evidence enables earlier intervention, more precise risk stratification, and more effective prevention strategies, ultimately contributing to a reduction in cardiovascular disease burden at both individual and population levels.

### **Conclusion**

The findings of this study confirm that the systematic implementation of evidence-based medicine significantly enhances the quality and effectiveness of both diagnostic and preventive strategies for cardiovascular diseases. Evidence-based diagnostic algorithms integrating biomarkers, non-invasive imaging techniques, and multivariable risk assessment models enable earlier detection of cardiovascular pathology and more accurate identification of high-risk individuals.

The results demonstrate that preventive interventions grounded in robust clinical evidence, particularly lifestyle modification and pharmacological prevention tailored to individual risk profiles, substantially reduce cardiovascular morbidity and mortality. Combined preventive approaches provide the greatest benefit, emphasizing the importance of integrated strategies rather than isolated interventions.

The study highlights that successful implementation of evidence-based medicine in cardiovascular care requires not only the availability of clinical guidelines but also their effective integration into routine clinical practice through professional education, decision-support tools, and digital health technologies. Embedding evidence-based principles at all stages of diagnosis and prevention is essential for optimizing cardiovascular outcomes and reducing the long-term burden of cardiovascular diseases at both individual and population levels.

### **References**

1. American Heart Association. (2022). Heart disease and stroke statistics—2022 update. *Circulation*, 145(8), e153–e639. <https://doi.org/10.1161/CIR.0000000000001052>



2. European Society of Cardiology. (2021). ESC guidelines on cardiovascular disease prevention. *European Heart Journal*, 42(34), 3227–3337. <https://doi.org/10.1093/eurheartj/ehab484>
3. Haynes, R. B., Devereaux, P. J., & Guyatt, G. H. (2002). Physicians' and patients' choices in evidence based practice. *BMJ*, 324(7350), 1350. <https://doi.org/10.1136/bmj.324.7350.1350>
4. Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017). Development and validation of QRISK3. *BMJ*, 357, j2099. <https://doi.org/10.1136/bmj.j2099>
5. Piepoli, M. F., Hoes, A. W., Agewall, S., et al. (2016). European guidelines on cardiovascular disease prevention. *European Heart Journal*, 37(29), 2315–2381. <https://doi.org/10.1093/eurheartj/ehw106>
6. Yusuf, S., Joseph, P., Rangarajan, S., et al. (2020). Modifiable risk factors associated with myocardial infarction. *The Lancet*, 395(10226), 795–808. [https://doi.org/10.1016/S0140-6736\(20\)30226-9](https://doi.org/10.1016/S0140-6736(20)30226-9)
7. Ташпулатова, Ф. К., Садыков, А. С., & Галиуллин, Т. И. (2017). МЕДИКО-СОЦИАЛЬНЫЕ АСПЕКТЫ ТУБЕРКУЛЕЗА ЛЕГКИХ И ВИЧ. *Фтизиатрия и пульмонология*, (2), 136-136.
8. Bekembayeva, G. S., & Tashpulatova, F. K. (2021). PROGNOSIS OF RESISTANT TUBERCULOSIS COURSE AMONG CHILDREN AND TEENAGERS. *Новый день в медицине*, (1), 48-51.
9. Khomova, N., Tashpulatova, F., & Sultanov, S. (2017). Compliance-is patient adherence to treatment, as well as partnerships between doctor and patient.
10. Ташпулатова, Ф. К., Галиуллин, Т. И., & Жумаев, О. А. (2018). АССОЦИАЦИЯ РИСКА РАЗВИТИЯ КАЗЕОЗНОЙ ПНЕВМОНИИ ПРИ ТУБЕРКУЛЕЗЕ ЛЕГКИХ С ГЕНЕТИЧЕСКИМИ МАРКЕРАМИ. *Интернаука*, (14-1), 52-53.
11. Вахабов, А. А., & Ташпулатова, Ф. К. (2018). Поражение печени у больных туберкулезом легких при побочных реакциях от противотуберкулезных препаратов. *Молодой ученый*, (3), 91-93.
12. Хомова, Н. А., Коломиец, В. М., & Ташпулатова, Ф. К. (2020). Приверженность к лечению больных туберкулезом как фактор риска



- 
- снижения его эффективности. In Университетская наука: взгляд в будущее (pp. 314-319).
13. Tashpulatova, F., Shamshieva, N., Mukhteremova, V., Medvedeva, N., & Kurbanov, A. (2021). Phytotherapy in the Complex Treatment of Patients with Drug-Resistant Forms of Pulmonary Tuberculosis. *Annals of the Romanian Society for Cell Biology*, 25(1), 367-372.
  14. Ташпулатова, Ф. К., Жалолов, А. Ж., Медведева, Н. В., & Долгушева, Ю. В. (2016). Уровень комплаенса у больных с лекарственно устойчивым туберкулезом. In *Медицина: вызовы сегодняшнего дня* (pp. 46-50).
  15. Tashpulatova, F. K. (2003). Prevention of adverse reactions of antituberculous drugs in pulmonary tuberculosis in patients with different genetic background. *Problemy tuberkuleza i boleznei legkikh*, (6), 17-20.
  16. Ташпулатова, Ф. К. (2017). Выявление туберкулеза легких в общесоматических лечебных учреждениях. *Молодой ученый*, (3), 236-238.
  17. Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. *Новый день в медицине*, 2(30), 544-547.
  18. Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. *Новый день в медицине*, 2(30), 544-547.
  19. Isomov, M. M. (2020). Features of etiopathogenesis and the course of inflammatory processes of periapical tissues in women during pregnancy (review of literature)/Isomov MM, Shomurodov KE, Olimjonov KJ, Azimov IM. *Biomedicine and practice*.—2020.—№ SI-2, 833-838.
  20. Isomov, M. M., Shomurodov, K. E., Olimjonov, K. J., & Azimov, I. M. (2020). Features of etiopathogenesis and the course of inflammatory processes of periapical tissues in women during pregnancy. *Journal Biomedicine and Practice*, 833-838.
  21. Shomurodov, K. E., Kuryazova, Z. K., Isomov, M. M., Mukimov, I. I., & Fayziyev, B. R. (2017). Improvement of surgical treatment of fractures of the inferior orbit wall. *J Stomatologiya* 2017, 2, 78-80.



- 
22. Шомуродов, К. Э., & Исомов, М. М. (2020). Мониторинг стационарной и амбулаторной реабилитации беременных женщин с воспалительными заболеваниями ЧЛЮ. *Стоматология*, 1, 34-37.
23. Shomurodov, K. E., & Isomov, M. M. (2021). Cytokine profile of blood plasma and oral fluid in pregnant women with odontogenic inflammatory diseases. *Central Asian Journal of Medical and Natural Science*, 2(3), 118-122.
24. Исомов, М. М., Шомуродов, К. Э., & Ахмадалиев, Н. Н. (2020). Мониторинг госпитализированных беременных женщин с одонтогенными воспалительными заболеваниями ЧЛЮ за 2017-2019 гг. на базе клиники взрослой хирургической стоматологии ТГСИ. In *Инновационная стоматология* (pp. 116-119).
25. Мусаев, Ш., Шомуродов, К., & Исомов, М. (2020). Частота и характеристика переломов нижней челюсти у детей. *Стоматология*, 1(1 (78)), 45-48.
26. Шомуродов, К. Э., & Мирхусанова, Р. С. (2021). МРТ визуализация структур небно-глоточной области после уранопластики различными способами. In *Актуальные вопросы стоматологии детского возраста* (pp. 340-346).
27. Шомуродов, К. Э., & Мирхусанова, Р. С. (2020). АНАТОМО-ФУНКЦИОНАЛЬНОЕ СОСТОЯНИЕ МЯГКОГО НЁБА И ЯЗЫЧКА ПОСЛЕ УРАНОПЛАСТИКИ У ДЕТЕЙ С ВРОЖДЁННОЙ РАСЩЕЛИНОЙ НЁБА. In *СОВРЕМЕННЫЕ АСПЕКТЫ КОМПЛЕКСНОЙ СТОМАТОЛОГИЧЕСКОЙ РЕАБИЛИТАЦИИ ПАЦИЕНТОВ С ДЕФЕКТАМИ ЧЕЛЮСТНО-ЛИЦЕВОЙ ОБЛАСТИ* (pp. 187-191).
28. Садикова, Х., Махамов, Б., Абдувалиев, Н., Мамурбоева, М., & Исомов, М. (2019). Преимущества двухэтапной имплантации с применением пьезоинструментов для костного расщепления и аутогенной плазмы крови, обогащенной тромбоцитами. *Стоматология*, 1(1 (74)), 24-27.



- 
29. Шомуродов, К. Э., & Мирхусанова, Р. С. СРАВНИТЕЛЬНАЯ ОЦЕНКА СОСТОЯНИЯ НЕБНО-ГЛОТОЧНОГО КОЛЬЦА ПОСЛЕ УРАНОПЛАСТИКИ МЕТОДОМ МРТ. ББК, 56, 56.
30. Искандарова, Ш. Т., Расулова, Н. Ф., Хасанова, М. И., & Юсупалиева, К. Б. (2019). Современные проблемы гигиены почвы в условиях Узбекистана почвы в условиях Узбекистана Ташкент:" Фан.
31. Фахриев, Ж. А., Нозимова, Н. Х., & Расулова, Н. Ф. (2019). Сидячий образ жизни и его влияние на здоровье человека. Теория и практика современной науки, (3 (45)), 318-321.
32. Расулова, Н. Ф. (2016). Совершенствование методов этического воспитания медицинских сестёр лечебно-профилактических учреждений. Молодой ученый, (7), 409-412.
33. Rasulova, N. F., Jalilova, G. A., & Mukhamedova, N. S. (2023). PREVENTION OF IMPORTANT NON-COMMUNICABLE DISEASES AMONG THE POPULATION. Евразийский журнал медицинских и естественных наук, 3(1 Part 2), 2123.
34. Nazarova, S. K., Jalilova, G. A., Mukhamedova, N. S., & Rasulova, N. F. (2021). Features of distance learning organization. Annals of the Romanian Society for Cell Biology, 25(1), 339-347.
35. Усманов, И. А., Джалилова, Г. А., & Расулова, Н. Ф. (2016). К вопросу охраны водных объектов бассейна Амударьи на примере Кашкадарьинской области. Вестник науки и образования, (2 (14)), 95-98.
36. Мирзаева, М. А., & Расулова, Н. Ф. (2014). Компьютеризация рабочего места медицинских сестер стационара. Сборник статей и тезисов.
37. Расулова, Н. Ф. (2011). Ўзбекистонда педиатриянинг ривожланиш тарихи.
38. Rasulova, N., Abdullaev, K., & Kuddusova, K. (2024). THE INTEGRATED APPROACH TO THE TREATMENT OF PATIENTS WITH ATROPHIC RHINITIS WHO HAVE COVID-19. Science and innovation, 3(D7), 56-60.
39. Расулова, Н. Ф., & Асадова, Г. А. (2023). ИЗУЧЕНИЕ ОСОБЕННОСТИ ЗДОРОВЬЕСОХРАНЯЮЩЕГО ПОВЕДЕНИЯ И САМООЦЕНКА



***Modern American Journal of Medical and Health Sciences***

**ISSN (E): 3067-803X**

**Volume 2, Issue 2, February 2026**

**Website: usajournals.org**

***This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.***

---

ЗДОРОВЬЯ СТУДЕНТОВ. Science and innovation, 2(Special Issue 8), 978-980.

40. Abdullaev, N. J. (2019). Evidence-based approaches to cardiovascular disease prevention. *Medical Journal of Uzbekistan*, 4, 22–28.
41. Karimov, B. A., & Rakhimov, S. S. (2020). Cardiovascular risk assessment in primary healthcare. *Bulletin of Tashkent Medical Academy*, 3, 35–41.
42. Ismailova, D. K. (2018). Early diagnosis of cardiovascular diseases using clinical risk models. *Problems of Biology and Medicine*, 2, 54–59.
43. Yuldashev, A. K., & Mamatkulov, F. K. (2021). Implementation of evidence-based medicine in cardiology practice. *Informatics in Medicine*, 1, 31–38.
44. Saidova, G. N. (2017). Lifestyle modification in cardiovascular disease prevention. *Public Health of Uzbekistan*, 2, 18–24.
45. Tursunova, M. R. (2019). Preventive cardiology: Evidence-based strategies. *Journal of Hygiene and Epidemiology of Uzbekistan*, 3, 27–33.
46. Makhmudov, B. S. (2020). Clinical guidelines and their role in cardiovascular prevention. *Healthcare Management Review of Uzbekistan*, 1, 44–49.
47. World Health Organization. (2021). *Cardiovascular diseases (CVDs): Key facts*. WHO Press.
48. World Health Organization. (2022). *Consolidated guidelines on cardiovascular disease prevention*. WHO Press.